AL001 + Lithium Carbonate Capsule
Phase 1Active 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pharmacokinetics
Conditions
Pharmacokinetics, Neurology
Trial Timeline
May 9, 2025 → Dec 1, 2025
NCT ID
NCT06921590About AL001 + Lithium Carbonate Capsule
AL001 + Lithium Carbonate Capsule is a phase 1 stage product being developed by Alzamend Neuro for Pharmacokinetics. The current trial status is active. This product is registered under clinical trial identifier NCT06921590. Target conditions include Pharmacokinetics, Neurology.
What happened to similar drugs?
5 of 5 similar drugs in Pharmacokinetics were approved
Approved (5) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06921590 | Phase 1 | Active |
Competing Products
20 competing products in Pharmacokinetics